Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 1, 2011, Pages 41-50

  Lemon, Douglas D ^a   Horn, Todd R ^a   Cavasin, Maria A ^a   Jeong, Mark Y ^a   Haubold, Kurt W ^a   Long, Carlin S ^a   Irwin, David C ^a   McCune, Sylvia A ^b   Chung, Eunhee ^b   Leinwand, Leslie A ^b   McKinsey, Timothy A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiac hypertrophy; Heart failure; Histone deacetylase; Hypertension; Small molecule

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CATALYSIS; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FIBROBLAST; HEART HYPERTROPHY; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HEART STRESS; HYPERTENSION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT;

ADENOVIRIDAE; ANIMALS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; HEART VENTRICLES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYPERTENSION; MALE; MICE; MYOCARDIUM; MYOCYTES, CARDIAC; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VENTRICULAR REMODELING;

ANIMALIA;

EID: 79956317095     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.04.005     Document Type: Article

References (55)

1. Yip G.W., Fung J.W., Tan Y.T., Sanderson J.E. Hypertension and heart failure: a dysfunction of systole, diastole or both?. J Hum Hypertens 2009, 23:295-306.
2. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De S.G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
3. Berry J.M., Cao D.J., Rothermel B.A., Hill J.A. Histone deacetylase inhibition in the treatment of heart disease. Expert Opin Drug Saf 2008, 7:53-67.
4. Bush E.W., McKinsey T.A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010, 106:272-284.
5. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
6. Norris K.L., Lee J.Y., Yao T.P. Acetylation goes global: the emergence of acetylation biology. Sci Signal 2009, 2:e76.
7. Smith K.T., Workman J.L. Introducing the acetylome. Nat Biotechnol 2009, 27:917-919.
8. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338:17-31.
9. Granger A., Abdullah I., Huebner F., Stout A., Wang T., Huebner T., et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J 2008, 22:3549-3560.
10. Zhang L.X., Zhao Y., Cheng G., Guo T.L., Chin Y.E., Liu P.Y., et al. Targeted deletion of NF-kappaB p50 diminishes the cardioprotection of histone deacetylase inhibition. Am J Physiol Heart Circ Physiol 2010, 298:H2154-H2163.
11. Zhao T.C., Cheng G., Zhang L.X., Tseng Y.T., Padbury J.F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res 2007, 76:473-481.
12. Zhao T.C., Zhang L.X., Cheng G., Liu J.T. gp-91 mediates histone deacetylase inhibition-induced cardioprotection. Biochim Biophys Acta 2010, 1803:872-880.
13. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113:51-59.
14. Kong Y., Tannous P., Lu G., Berenji K., Rothermel B.A., Olson E.N., et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113:2579-2588.
15. Kook H., Lepore J.J., Gitler A.D., Lu M.M., Wing-Man Y.W., Mackay J., et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003, 112:863-871.
16. Iyer A., Fenning A., Lim J., Le G.T., Reid R.C., Halili M.A., et al. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol 2010, 159:1408-1417.
17. Cardinale J.P., Sriramula S., Pariaut R., Guggilam A., Mariappan N., Elks C.M., et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010, 56:437-444.
18. Cho Y.K., Eom G.H., Kee H.J., Kim H.S., Choi W.Y., Nam K.I., et al. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J 2010, 74:760-770.
19. Heltweg B., Dequiedt F., Marshall B.L., Brauch C., Yoshida M., Nishino N., et al. Subtype selective substrates for histone deacetylases. J Med Chem 2004, 47:5235-5243.
20. Crossno J.T., Garat C.V., Reusch J.E., Morris K.G., Dempsey E.C., McMurtry I.F., et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007, 292:L885-L897.
21. Bogaard H.J., Natarajan R., Henderson S.C., Long C.S., Kraskauskas D., Smithson L., et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation 2009, 120:1951-1960.
22. Taraseviciene-Stewart L., Kasahara Y., Alger L., Hirth P., Mc M.G., Waltenberger J., et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001, 15:427-438.
23. Lange D.L., Haywood J.R., Hinojosa-Laborde C. Endothelin enhances and inhibits adrenal catecholamine release in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 2000, 35:385-390.
24. Qualy J.M., Westfall T.C. Overflow of endogenous norepinephrine from PVH nucleus of DOCA-salt hypertensive rats. Am J Physiol 1995, 268:H1549-H1554.
25. Konhilas J.P., Watson P.A., Maass A., Boucek D.M., Horn T., Stauffer B.L., et al. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 2006, 98:540-548.
26. Onodera T., Tamura T., Said S., McCune S.A., Gerdes A.M. Maladaptive remodeling of cardiac myocyte shape begins long before failure in hypertension. Hypertension 1998, 32:753-757.
27. Sack M.N., Rader T.A., Park S., Bastin J., McCune S.A., Kelly D.P. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996, 94:2837-2842.
28. Palmer J.N., Hartogensis W.E., Patten M., Fortuin F.D., Long C.S. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. J Clin Invest 1995, 95:2555-2564.
29. Satoh N., Suter T.M., Liao R., Colucci W.S. Chronic alpha-adrenergic receptor stimulation modulates the contractile phenotype of cardiac myocytes in vitro. Circulation 2000, 102:2249-2254.
30. Hoffmann K., Brosch G., Loidl P., Jung M. A non-isotopic assay for histone deacetylase activity. Nucleic Acids Res 1999, 27:2057-2058.
31. Riester D., Wegener D., Hildmann C., Schwienhorst A. Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates. Biochem Biophys Res Commun 2004, 324:1116-1123.
32. Jones P., Altamura S., De F.R., Gallinari P., Lahm A., Neddermann P., et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 2008, 18:1814-1819.
33. Lahm A., Paolini C., Pallaoro M., Nardi M.C., Jones P., Neddermann P., et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A 2007, 104:17335-17340.
34. Bitterman K.J., Anderson R.M., Cohen H.Y., Latorre-Esteves M., Sinclair D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002, 277:45099-45107.
35. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
36. Bogaard H.J., Natarajan R., Mizuno S., Abbate A., Chang P.J., Chau V.Q., et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010, 182:652-660.
37. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
38. Tobise K., Ishikawa Y., Holmer S.R., Im M.J., Newell J.B., Yoshie H., et al. Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle. Circ Res 1994, 74:596-603.
39. Butler K.V., Kalin J., Brochier C., Vistoli G., Langley B., Kozikowski A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010, 132:10842-10846.
40. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15:3958-3969.
41. Kee H.J., Eom G.H., Joung H., Shin S., Kim J.R., Cho Y.K., et al. Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ Res 2008, 103:1259-1269.
42. Zhu H., Shan L., Schiller P.W., Mai A., Peng T. Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem 2010, 285:9429-9436.
43. Shaw J., Zhang T., Rzeszutek M., Yurkova N., Baetz D., Davie J.R., et al. Transcriptional silencing of the death gene BNIP3 by cooperative action of NF-kappaB and histone deacetylase 1 in ventricular myocytes. Circ Res 2006, 99:1347-1354.
44. Marks P.A. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs 2010, 19:1049-1066.
45. Balasubramanian S., Verner E., Buggy J.J. Isoform-specific histone deacetylase inhibitors: the next step?. Cancer Lett 2009, 280:211-221.
46. Horwitz S.M. The emerging role of histone deacetylase inhibitors in treating t-cell lymphomas. Curr Hematol Malig Rep 2011, 6:67-72.
47. Tokesi N., Lehotzky A., Horvath I., Szabo B., Olah J., Lau P., et al. TPPP/p25 promotes tubulin acetylation by inhibiting histone deacetylase 6. J Biol Chem 2010, 285:17896-17906.
48. Wickstrom S.A., Masoumi K.C., Khochbin S., Fassler R., Massoumi R. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 2010, 29:131-144.
49. Wu Y., Song S.W., Sun J., Bruner J.M., Fuller G.N., Zhang W. IIp45 inhibits cell migration through inhibition of HDAC6. J Biol Chem 2010, 285:3554-3560.
50. Perez M., Santa-Maria I., Gomez de B.E., Zhu X., Cuadros R., Cabrero J.R., et al. Tau-an inhibitor of deacetylase HDAC6 function. J Neurochem 2009, 109:1756-1766.
51. Deribe Y.L., Wild P., Chandrashaker A., Curak J., Schmidt M.H., Kalaidzidis Y., et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal 2009, 2:ra84.
52. Han Y., Jeong H.M., Jin Y.H., Kim Y.J., Jeong H.G., Yeo C.Y., et al. Acetylation of histone deacetylase 6 by p300 attenuates its deacetylase activity. Biochem Biophys Res Commun 2009, 383:88-92.
53. Chen S., Owens G.C., Makarenkova H., Edelman D.B. HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One 2010, 5:e10848.
54. Zhang Y., Kwon S., Yamaguchi T., Cubizolles F., Rousseaux S., Kneissel M., et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol 2008, 28:1688-1701.
55. Lee J.Y., Yao T.P. Quality control autophagy: A joint effort of ubiquitin, protein deacetylase and actin cytoskeleton. Autophagy 2010, 6.